According to the AI news, the US stock market of Bristol Myers Squibb rose more than 5% before trading. The US regulatory authorities approved its Cobenfy for the treatment of schizophrenia, which is ...

On September 27th, the US stock market of Bristol Myers Squibb rose more than 5% before trading, as US regulatory authorities approved its Cobenfy for the treatment of schizophrenia, the first drug a ...